Sight Sciences, Inc. (NASDAQ:SGHT) EVP Manohar K. Raheja Purchases 10,000 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) EVP Manohar K. Raheja acquired 10,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was acquired at an average price of $2.73 per share, for a total transaction of $27,300.00. Following the purchase, the executive vice president now directly owns 145,000 shares in the company, valued at approximately $395,850. This trade represents a 7.41 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

Sight Sciences Trading Up 13.3 %

Shares of SGHT stock opened at $2.72 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The company has a market cap of $139.63 million, a price-to-earnings ratio of -2.67 and a beta of 2.52. The stock has a 50 day simple moving average of $2.80 and a 200-day simple moving average of $4.25. Sight Sciences, Inc. has a 1-year low of $2.17 and a 1-year high of $8.45.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The firm had revenue of $19.07 million during the quarter, compared to analyst estimates of $18.98 million. During the same period in the prior year, the company posted ($0.22) earnings per share. On average, equities research analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Sight Sciences

A number of hedge funds have recently modified their holdings of the business. American Century Companies Inc. boosted its holdings in Sight Sciences by 10.7% during the 4th quarter. American Century Companies Inc. now owns 51,564 shares of the company’s stock valued at $188,000 after acquiring an additional 4,964 shares during the period. SG Americas Securities LLC increased its position in Sight Sciences by 47.6% during the fourth quarter. SG Americas Securities LLC now owns 17,622 shares of the company’s stock worth $64,000 after buying an additional 5,681 shares during the period. Wells Fargo & Company MN increased its position in Sight Sciences by 53.4% during the fourth quarter. Wells Fargo & Company MN now owns 16,600 shares of the company’s stock worth $60,000 after buying an additional 5,781 shares during the period. Barclays PLC increased its position in Sight Sciences by 11.9% during the fourth quarter. Barclays PLC now owns 56,294 shares of the company’s stock worth $205,000 after buying an additional 5,994 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Sight Sciences by 2.1% in the 4th quarter. Northern Trust Corp now owns 332,491 shares of the company’s stock valued at $1,210,000 after purchasing an additional 6,727 shares during the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SGHT. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a report on Thursday, March 6th. Stifel Nicolaus cut their target price on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Citigroup dropped their price objective on shares of Sight Sciences from $4.60 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Lake Street Capital decreased their target price on Sight Sciences from $3.00 to $2.50 and set a “hold” rating for the company in a research report on Thursday, March 6th. Finally, UBS Group decreased their target price on Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research report on Monday, January 27th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Sight Sciences currently has an average rating of “Hold” and an average target price of $3.83.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.